Esperion Therapeutis.Inc. buy OrderProvision70
Start price
18.04.25
/
50%
€0.79
Target price
18.05.25
-
Performance (%)
-8.23%
End price
19.05.25
€0.72
Summary
This prediction ended on 19.05.25 with a price of €0.72. With a performance of -8.23%, the BUY prediction by OrderProvision70 finished with a loss. OrderProvision70 has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Esperion Therapeutis.Inc. | 2.803% | 2.803% |
| iShares Core DAX® | -0,82 % | -2,03 % |
| iShares Nasdaq 100 | -1,74 % | -5,35 % |
| iShares Nikkei 225® | 1,21 % | 6,38 % |
| iShares S&P 500 | -1,17 % | -3,46 % |
Comments by OrderProvision70 for this prediction
In the thread Trading Esperion Therapeutis.Inc.
Die von OrderProvision70 gewählte maximale Laufzeit wurde überschritten